Related references
Note: Only part of the references are listed.Pharmacometrics for Regulatory Decision Making Status and Perspective
Efthymios Manolis et al.
CLINICAL PHARMACOKINETICS (2011)
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Role of modeling and simulation in pediatric investigation plans
Efthymios Manolis et al.
PEDIATRIC ANESTHESIA (2011)
Pharmacometrics 2020
Jogarao V. S. Gobburu
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Model-Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development
Jeffrey D. Wetherington et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Model-Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry
Julie A. Stone et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Proposals for model-based paediatric medicinal development within the current European Union regulatory framework
Efthymios Manolis et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Regulatory Aspects of Pharmacokinetic Profiling in Special Populations A European Perspective
Monica Edholm et al.
CLINICAL PHARMACOKINETICS (2008)
Randomized exposure-controlled trials;: impact of randomization and analysis strategies
Kristin E. Karlsson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Model-based drug development
R. L. Lalonde et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Paving the critical path: How can clinical pharmacology help achieve the vision?
L. J. Lesko
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease
Peter Lockwood et al.
PHARMACEUTICAL RESEARCH (2006)
Model-based drug development: The road to quantitative pharmacology
Liping Zhang et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2006)
Getting the Dose Right: Report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development
DR Stanski et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2005)
How modeling and simulation have enhanced decision making in new drug development
R Miller et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2005)
Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation
JY Chien et al.
AAPS JOURNAL (2005)
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: The capecitabine experience
KS Blesch et al.
INVESTIGATIONAL NEW DRUGS (2003)
Pharmacokinetic/pharmacodynamic studies in drug product development
B Meibohm et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization
C Veyrat-Follet et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Modelling during drug development
LP Balant et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2000)
Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process - Experience at Parke-Davis
SC Olson et al.
CLINICAL PHARMACOKINETICS (2000)
Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development
R Gieschke et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2000)
Share Paper
